Journal article
Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study
AZ Bujak, CF Weng, MJ Silva, M Yeung, L Lo, S Ftouni, C Litchfield, YA Ko, K Kuykhoven, C van Geelen, S Chandrashekar, MA Dawson, S Loi, SQ Wong, SJ Dawson
Plos Medicine | PUBLIC LIBRARY SCIENCE | Published : 2020
Abstract
Background Metastatic breast cancer (mBC) is a heterogenous disease with increasing availability of targeted therapies as well as emerging genomic markers of therapeutic resistance, necessitating timely and accurate molecular characterization of disease. As a minimally invasive test, analysis of circulating tumour DNA (ctDNA) is well positioned for real-time genomic profiling to guide treatment decisions. Here, we report the results of a prospective testing program established to assess the feasibility of ctDNA analysis to guide clinical management of mBC patients. Methods and findings Two hundred thirty-four mBC patients (median age 54 years) were enrolled between June 2015 and October 2018..
View full abstractGrants
Awarded by National Breast Cancer Foundation
Funding Acknowledgements
S-J.D and A.Z.B. received funding for this research. S-J.D received funding through the National Health and Medical Research Council of Australia (grant number APP1085014, https://www.nhmrc.gov.au), the Peter MacCallum Cancer Centre Women's Cancer Research Program (https://www.petermac.org), Genentech (https://www.gene.com), and the Australian Cancer Research Foundation (https://www.acrf.com.au).S-J.D.was supported by a National Breast Cancer Foundation (https://nbcf.org.au) and Victorian Cancer Agency (http://victoriancanceragency.vic.gov.au) Fellowship and a CSL Centenary Fellowship (https://www.cslfellowships.com.au).A.Z.B.was supported by an Australian Postgraduate Award administered by the University of Melbourne (https://www.unimelb.edu.au) and a PhD Top Up Scholarship administered by Cancer Therapeutics CRC, Melbourne, Australia (https://cancercrc.com).The funders played no role in the study design, data collection and analysis, decision to publish, or the preparation of the manuscript.